First biologic for severe eczema okayed for teens

Although it is confined to the private market, there is a renewed bid for PBS listing

The first targeted biologic to treat moderate-to-severe atopic dermatitis can now be prescribed to patients as young as 12 via private script.

Dermatitis

Dupilumab (Dupixent) is an alternative to topical corticosteroids and topical calcineurin inhibitors that is TGA registered for use in adults, and now adolescents, with severe forms of atopic dermatitis.

The monoclonal antibody selectively inhibits the signaling of type two cytokines, interleukin-4 and interleukin-13.

But with a price tag of $1615.38 for two 300mg injections — which is the

Latest

Trending